Literature DB >> 24730660

The evolution of three decades of antiretroviral therapy: challenges, triumphs and the promise of the future.

Alice Tseng1, Jason Seet, Elizabeth J Phillips.   

Abstract

The evolution of human immunodeficiency virus (HIV) treatment has improved our understanding and management of complex pharmacological issues that have driven improved outcomes and quality of life of the HIV-infected patient. These issues include adherence, long- and short-term toxicities, pharmacoenhancement, pharmacogenomics, therapeutic drug monitoring, differential penetration of drugs into sanctuary sites, such as the central nervous system, genital tract and small bowel, and drug-drug and drug-food interactions related to cytochrome P450 drug-metabolizing enzymes, uridine diphosphate glucuronyltransferases and drug transporters, to name a few. There is future promise, as an increased understanding of the immunopathogenesis of HIV and global public health initiatives are driving novel treatment approaches with goals to prevent, control and, ultimately, eradicate HIV.
© 2014 The British Pharmacological Society.

Entities:  

Keywords:  adherence; antiretroviral; drug interactions; human immunodeficiency virus; pharmacogenomics; therapeutic drug monitoring

Mesh:

Substances:

Year:  2015        PMID: 24730660      PMCID: PMC4309625          DOI: 10.1111/bcp.12403

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  65 in total

1.  Finding the right chemistry.

Authors:  Killugudi Jayaraman
Journal:  Nat Med       Date:  2013-10       Impact factor: 53.440

2.  Optimising the manufacture, formulation, and dose of antiretroviral drugs for more cost-efficient delivery in resource-limited settings: a consensus statement.

Authors:  Keith W Crawford; David H Brown Ripin; Andrew D Levin; Jennifer R Campbell; Charles Flexner
Journal:  Lancet Infect Dis       Date:  2012-07       Impact factor: 25.071

3.  Cost-effectiveness of HIV treatment as prevention in serodiscordant couples.

Authors:  Rochelle P Walensky; Eric L Ross; Nagalingeswaran Kumarasamy; Robin Wood; Farzad Noubary; A David Paltiel; Yoriko M Nakamura; Sheela V Godbole; Ravindre Panchia; Ian Sanne; Milton C Weinstein; Elena Losina; Kenneth H Mayer; Ying Q Chen; Lei Wang; Marybeth McCauley; Theresa Gamble; George R Seage; Myron S Cohen; Kenneth A Freedberg
Journal:  N Engl J Med       Date:  2013-10-31       Impact factor: 91.245

Review 4.  Pharmacokinetics and pharmacodynamics in HIV prevention; current status and future directions: a summary of the DAIDS and BMGF sponsored think tank on pharmacokinetics (PK)/pharmacodynamics (PD) in HIV prevention.

Authors:  Joseph Romano; Angela Kashuba; Stephen Becker; James Cummins; Jim Turpin; Fulvia Veronese
Journal:  AIDS Res Hum Retroviruses       Date:  2013-05-22       Impact factor: 2.205

5.  Important Drug-Drug Interactions in HIV-Infected Persons on Antiretroviral Therapy: An Update on New Interactions Between HIV and Non-HIV Drugs.

Authors:  Alice Tseng; Michelle Foisy
Journal:  Curr Infect Dis Rep       Date:  2012-02       Impact factor: 3.725

6.  Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.

Authors:  Michael C Thigpen; Poloko M Kebaabetswe; Lynn A Paxton; Dawn K Smith; Charles E Rose; Tebogo M Segolodi; Faith L Henderson; Sonal R Pathak; Fatma A Soud; Kata L Chillag; Rodreck Mutanhaurwa; Lovemore Ian Chirwa; Michael Kasonde; Daniel Abebe; Evans Buliva; Roman J Gvetadze; Sandra Johnson; Thom Sukalac; Vasavi T Thomas; Clyde Hart; Jeffrey A Johnson; C Kevin Malotte; Craig W Hendrix; John T Brooks
Journal:  N Engl J Med       Date:  2012-07-11       Impact factor: 91.245

7.  Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.

Authors:  Jared M Baeten; Deborah Donnell; Patrick Ndase; Nelly R Mugo; James D Campbell; Jonathan Wangisi; Jordan W Tappero; Elizabeth A Bukusi; Craig R Cohen; Elly Katabira; Allan Ronald; Elioda Tumwesigye; Edwin Were; Kenneth H Fife; James Kiarie; Carey Farquhar; Grace John-Stewart; Aloysious Kakia; Josephine Odoyo; Akasiima Mucunguzi; Edith Nakku-Joloba; Rogers Twesigye; Kenneth Ngure; Cosmas Apaka; Harrison Tamooh; Fridah Gabona; Andrew Mujugira; Dana Panteleeff; Katherine K Thomas; Lara Kidoguchi; Meighan Krows; Jennifer Revall; Susan Morrison; Harald Haugen; Mira Emmanuel-Ogier; Lisa Ondrejcek; Robert W Coombs; Lisa Frenkel; Craig Hendrix; Namandjé N Bumpus; David Bangsberg; Jessica E Haberer; Wendy S Stevens; Jairam R Lingappa; Connie Celum
Journal:  N Engl J Med       Date:  2012-07-11       Impact factor: 91.245

Review 8.  Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients.

Authors:  Robert K Zeldin; Richard A Petruschke
Journal:  J Antimicrob Chemother       Date:  2003-12-04       Impact factor: 5.790

9.  Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26.

Authors:  Hiroyuki Gatanaga; Tsunefusa Hayashida; Kiyoto Tsuchiya; Munehiro Yoshino; Takeshi Kuwahara; Hiroki Tsukada; Katsuya Fujimoto; Isao Sato; Mikio Ueda; Masahide Horiba; Motohiro Hamaguchi; Masahiro Yamamoto; Noboru Takata; Akiro Kimura; Takao Koike; Fumitake Gejyo; Shuzo Matsushita; Takuma Shirasaka; Satoshi Kimura; Shinichi Oka
Journal:  Clin Infect Dis       Date:  2007-09-24       Impact factor: 9.079

10.  Challenges in detecting HIV persistence during potentially curative interventions: a study of the Berlin patient.

Authors:  Steven A Yukl; Eli Boritz; Michael Busch; Christopher Bentsen; Tae-Wook Chun; Daniel Douek; Evelyn Eisele; Ashley Haase; Ya-Chi Ho; Gero Hütter; J Shawn Justement; Sheila Keating; Tzong-Hae Lee; Peilin Li; Danielle Murray; Sarah Palmer; Christopher Pilcher; Satish Pillai; Richard W Price; Meghan Rothenberger; Timothy Schacker; Janet Siliciano; Robert Siliciano; Elizabeth Sinclair; Matt Strain; Joseph Wong; Douglas Richman; Steven G Deeks
Journal:  PLoS Pathog       Date:  2013-05-09       Impact factor: 6.823

View more
  32 in total

1.  Pharmacokinetics of efavirenz in patients on antituberculosis treatment in high human immunodeficiency virus and tuberculosis burden countries: A systematic review.

Authors:  Daniel Atwine; Maryline Bonnet; Anne-Marie Taburet
Journal:  Br J Clin Pharmacol       Date:  2018-05-22       Impact factor: 4.335

2.  The HEPT Analogue WPR-6 Is Active against a Broad Spectrum of Nonnucleoside Reverse Transcriptase Drug-Resistant HIV-1 Strains of Different Serotypes.

Authors:  Weisi Xu; Jianxiong Zhao; Jianping Sun; Qianqian Yin; Yan Wang; Yang Jiao; Junyi Liu; Shibo Jiang; Yiming Shao; Xiaowei Wang; Liying Ma
Journal:  Antimicrob Agents Chemother       Date:  2015-06-08       Impact factor: 5.191

3.  From an evolutionary perspective, all 'new' antimicrobial targets are old: time to think outside the box.

Authors:  Jennifer H Martin; Albert Ferro
Journal:  Br J Clin Pharmacol       Date:  2015-02       Impact factor: 4.335

Review 4.  Novel Antiretroviral Drugs in Patients with Renal Impairment: Clinical and Pharmacokinetic Considerations.

Authors:  Dario Cattaneo; Cristina Gervasoni
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-08       Impact factor: 2.441

5.  Therapeutic drug monitoring in the era of precision medicine: opportunities!

Authors:  Serge Cremers; Nishan Guha; Brian Shine
Journal:  Br J Clin Pharmacol       Date:  2016-10       Impact factor: 4.335

6.  An update on the Barriers to Adherence and a Definition of Self-Report Non-adherence Given Advancements in Antiretroviral Therapy (ART).

Authors:  John A Sauceda; Torsten B Neilands; Mallory O Johnson; Parya Saberi
Journal:  AIDS Behav       Date:  2018-03

7.  Out of Date or Best Before? A Commentary on the Relevance of Economic Evaluations Over Time.

Authors:  Gemma E Shields; Becky Pennington; Ash Bullement; Stuart Wright; Jamie Elvidge
Journal:  Pharmacoeconomics       Date:  2021-12-06       Impact factor: 4.981

8.  Trends in Use of Combination Antiretroviral Therapy and Treatment Response from 2000 to 2016 in the Canadian Observational Cohort (CANOC): A Longitudinal Cohort Study.

Authors:  Alison R McClean; Jason Trigg; Claudette Cardinal; Mona Loutfy; Curtis Cooper; Abigail Kroch; Mostafa Shokoohi; Nimâ Machouf; Réjean Thomas; Marina B Klein; Deborah V Kelly; Alexander Wong; Stephen Sanche; Julio S G Montaner; Robert S Hogg
Journal:  Can J Hosp Pharm       Date:  2022-10-03

9.  Memory Impairment in HIV-Infected Individuals with Early and Late Initiation of Regular Marijuana Use.

Authors:  Linda M Skalski; Sheri L Towe; Kathleen J Sikkema; Christina S Meade
Journal:  AIDS Behav       Date:  2018-05

10.  Understanding patterns of HIV multi-drug resistance through models of temporal and spatial drug heterogeneity.

Authors:  Alison F Feder; Kristin N Harper; Chanson J Brumme; Pleuni S Pennings
Journal:  Elife       Date:  2021-09-02       Impact factor: 8.140

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.